Objective: To study the clinical and pathological correlations of neuromuscular patients with a high aldolase and normal creatine kinase (CK) in serum at presentation or during a symptomatic ...

Over the last several years, application of these newer tools and technologies have begun coming to fruition. Advancements include the characterization of K 2p 2.1, a potassium channel that may ...

Abstract Trichinellosis is a zoonosis results from eating raw or semi-cooked meat of infected animals. Medicinal plants have been used lately as alternatives and/or combined therapies to resolve some ...

Localized bioimpedance (BIA) was measured with a single frequency phase-sensitive analyzer at 50 kHz in three post-traumatic types of injuries on four professional soccer players: (1) myositis ...

Results Of 460 patients with IIM, we diagnosed 73 (16%) as having inclusion body myositis (IBM). Of 387 patients with IIMs other than IBM, the frequencies of anti-SRP and anti-HMGCR antibodies were 18 ...

In the previous studies on French and Japanese cohorts, the musculoskeletal histopathological performance of only 22 IIM patients with anti-Ku-positive was described. 3–5 The main pathological ...

Sporadic Inclusion Body Myositis-Diagnosis, Pathogenesis and Therapeutic Strategies Marinos C. Dalakas Disclosures Nat Clin Pract Neurol. 2006;2 (8):437-447. 0 ...

In individuals with myositis ossificans, the initial X-ray findings (small calcifications) appear two to six weeks after the trauma (6). Although it is called myositis, there is no inflammatory ...

Background Olympic weightlifting and powerlifting are two sports that expose the body to great forces. Injury characteristics have not been systematically reviewed for these two growing sports.

Summary: Authors in this study previously reported that BYL719, an inhibitor of PI3Kα, suppressed heterotopic ossification in mice model of a human genetic disease, fibrodysplasia ossificans ...

The table below is a review of notable updates that occurred in May 2025 for investigational products in development (not an inclusive list). Click on the status to view our full coverage.

Investor Contact: Ian Estepan 617-274-4052 iestepan@sarepta.com Media Contacts: Tracy Sorrentino 617-301-8566 tsorrentino@sarepta.com Kara Hoeger 617-710-3898 KHoeger@sarepta.com ...